Zebutinib works by inhibiting the activity of Bruton’s tyrosine kinase (BTK), which kills tumor cells in the body by regulating the B-cell receptor signaling pathway and affecting B-cell proliferation, apoptosis, differentiation and development. Zebutinib is a Bruton’s tyrosine kinase (BTK) inhibitor, which can be used as a targeted therapeutic agent for the treatment of set cell lymphoma, chronic lymphocytic leukemia and other hematologic malignancies. Zebutinib inhibits the activity of Bruton’s tyrosine kinase in the human body, thus exerting therapeutic effects. When taking Zebutinib targeted therapy, it may lead to bone marrow suppression, which may cause severe anemia, leukopenia and thrombocytopenia and other adverse reactions, and it is necessary to actively correct the anemia, raise leukocytes and platelets and other symptomatic treatments, so as to facilitate the patient’s ability to continue to tolerate Zebutinib treatment. Zebutinib is metabolized by the liver and kidney, and in the event of severe hepatic or renal impairment, the patient should be evaluated by a specialist physician to determine whether to adjust the dose of the drug or to discontinue the drug, and to actively protect the liver and kidney. Zebutinib is not recommended for use in pregnant women, women who are preparing for pregnancy and women who are breastfeeding. Zebutinib should be taken under the guidance of a medical professional, and regular blood tests, biochemistry, bone marrow aspiration, PET-CT and other tests should be conducted to assess the condition and the efficacy of the drug.